Mauricio Hong, MD
Clinical Cardiac Electrophysiology · Austin, TXNPI 1073710067
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Abbott at 56.4% of the total. Reporting peaked in 2019 at $23,922 and has fallen 79.0% since, to $5,027 in 2025.
Across 345 payments — averaging $230.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$45K
- Medtronic$13K
- Sanofi-aventis U.S. LLC$10K
- E.r. Squibb & Sons, L.L.C.$9K
- Boston Scientific$784
- Janssen Research & Development, LLC$582
- plus $1K from 11 others
Across 194 payments — averaging $3074.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$348K
- Medtronic$170K
- Abbott$78K
- Novartis$476
Across 4 payments — averaging $12,500 each. An ownership or investment interest held by the physician or an immediate family member.
- Valencia Technologies Corporation$50K
What the payments were for
- Consulting fees$38,69649%
- Speaking & faculty fees$25,79032%
- Travel & lodging$4,7786%
- Food & beverage$9,99613%
- Education$2130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 189 | $44,784 |
| Medtronic(3 entities) | 93 | $13,165 |
| Sanofi-aventis U.S. LLC | 6 | $10,178 |
| E.r. Squibb & Sons, L.L.C. | 10 | $8,970 |
| Boston Scientific | 15 | $784 |
| Janssen Research & Development, LLC | 7 | $582 |
| Cvrx, Inc. | 2 | $301 |
| Biosense Webster, Inc. | 13 | $290 |
| Biotronik Inc. | 2 | $122 |
| Heartflow, Inc. | 1 | $103 |
| Pfizer | 1 | $81 |
| Cardiva Medical, Inc. | 1 | $26 |
| Atricure, Inc. | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Bardy Diagnostics, Inc. | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Accent Pacemaker$8,925
- ELIQUIS$8,866
- MULTAQ$6,875
- Quadra Allure MP RF CRT Pacemkr$6,467
- ENSITE$6,300
- Ensite Cardiac Mapping System$5,876
- Quadra Assura CRT Defibrillator$4,635
- GALLANT$3,413
- ALLURE$3,413
- DISEASE STATE$3,303
- Reveal LINQ$3,146
- AVEIR$1,863
- EVERA MRI XT DR SURESCAN$1,132
- Micra$613
- ENSITE PRECISION$307
- Barostim Neo System$301
- ADVISOR$171
- Assurity Pacemaker$152
- WATCHMAN Access System$148
- Confirm Rx$143
How this compares
$79,473 in reported general payments places this provider in the 80th percentile of 233 clinical cardiac electrophysiology providers in Texas.
See all clinical cardiac electrophysiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 560 | $511,798 |
| XareltoRivaroxaban | 47 | $51,586 |
| MultaqDronedarone Hcl | 39 | $44,661 |
| Dofetilide | 83 | $10,489 |
| Metoprolol Succinate | 358 | $5,238 |
| Amiodarone Hcl | 206 | $4,647 |
| Flecainide Acetate | 66 | $3,015 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 16 | $2,519 |
| Mexiletine Hcl | 12 | $1,209 |
| Metoprolol Tartrate | 130 | $903 |
| Bisoprolol Fumarate | 24 | $616 |
| Doxycycline Monohydrate | 74 | $566 |
| Digoxin | 12 | $348 |
| Warfarin Sodium | 22 | $341 |
| Sucralfate | 16 | $153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $81 | $511,798560 claims |
| Sanofi-aventis U.S. LLCMultaq | $10,178 | $44,66139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 233 clinical cardiac electrophysiology providers in Texas.
Other clinical cardiac electrophysiology in Austin
- Andrea NataleAustin$1.3M
- Jason ZagrodzkyAustin$961K
- Amin Al-AhmadAustin$771K
- Rodney HortonAustin$553K
- Robert CanbyAustin$224K
- Weeranun BodeAustin$178K
- David TschoppAustin$114K
- Michael DelaughterBedford$1.6M
- Dale YooMcKinney$585K
- Jose Cuellar SilvaWebster$502K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.